- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 243/12 - Benzodiazépines-1, 5Benzodiazépines-1, 5 hydrogénées
Détention brevets de la classe C07D 243/12
Brevets de cette classe: 97
Historique des publications depuis 10 ans
6
|
9
|
9
|
10
|
8
|
2
|
6
|
3
|
2
|
0
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
Proprétaire |
Total
|
Cette classe
|
---|---|---|
Nippon Chemiphar Co., Ltd. | 236 |
10 |
Otsuka Pharmaceutical Co., Ltd. | 1544 |
6 |
The Johns Hopkins University | 5554 |
5 |
Purdue Research Foundation | 3489 |
5 |
The Governors of the University of Alberta | 886 |
4 |
Zeria Pharmaceutical Co., Ltd. | 92 |
4 |
Lieber Institute, Inc. | 38 |
4 |
F. Hoffmann-La Roche AG | 7961 |
3 |
Constellation Pharmaceuticals, Inc. | 210 |
3 |
Sanford Burnham Prebys Medical Discovery Institute | 285 |
3 |
Hoffmann-La Roche Inc. | 3303 |
2 |
Genentech, Inc. | 3886 |
2 |
Bayer AG | 3226 |
2 |
Bayer Pharma AG | 1086 |
2 |
The Regents of the University of Michigan | 4596 |
2 |
Commonwealth Scientific and Industrial Research Organisation | 1677 |
2 |
Sanford-Burnham Medical Research Institute | 128 |
2 |
Universita' degli Studi di Milano | 228 |
2 |
University of Pittsburgh - Of the Commonwealth System of Higher Education | 3058 |
2 |
Ventana Medical Systems, Inc. | 1025 |
2 |
Autres propriétaires | 30 |